Soft Gel Vaginal Estradiol Composition for Better Treatment Compliance

Solution Overview

Problem

Existing treatments for vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD) face compliance issues due to the form of estrogen-based pharmaceuticals, leading to incomplete or discontinued treatment, and they do not effectively address symptoms such as vaginal dryness, dyspareunia, and increased vaginal pH.

Innovation Solution

A soft gel vaginal pharmaceutical composition containing solubilized estradiol is designed for improved safety, ease of administration, and enhanced efficacy, with adjustable dosages to ensure clinical response, including manual or digital insertion and use of a suppository form.

Engineering Contradictions & Design Principles

VSEngineering Contradiction Analysis

1Reliability

If existing estrogen-based pharmaceutical forms are used for VVA treatment, then estrogen therapy effectiveness is achieved, but patient compliance deteriorates due to formulation-related problems

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSEase of operation

Solution Approach 1:

The patent changes the physical and chemical parameters of the estradiol formulation by solubilizing it in specific carriers (e.g., caprylic/capric triglyceride, medium chain fatty acid esters) and adjusting the dosage form parameters (suppository, cream, or gel). This transformation improves patient compliance by making the formulation more acceptable and easier to administer while maintaining treatment effectiveness through controlled release and optimized bioavailability.

Inventive Principle:
Principle #35Parameter changes

2Reliability

If conventional vaginal estradiol formulations are used, then VVA symptoms are treated, but vaginal discharge increases causing discomfort

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-generated harmful factors

Solution Approach 1:

The patent applies local quality by formulating estradiol with specific carriers and adjuvants that provide different properties at different locations within the vaginal tissue. The solubilized estradiol in oil-based carriers provides targeted local effect at the vaginal mucosa while minimizing systemic absorption and discharge. The formulation creates a localized therapeutic zone that treats VVA symptoms without causing excessive discharge.

Inventive Principle:
Principle #3Local quality

Solution Approach 2:

The patent uses intermediary substances (solubilizing agents like caprylic/capric triglyceride, medium chain fatty acid esters, and co-solvents) as mediators between the estradiol and the vaginal tissue. These intermediaries facilitate controlled delivery and absorption of estradiol while minimizing harmful effects such as discharge. The intermediaries act as carriers that regulate the release and distribution of the active ingredient.

Inventive Principle:
Principle #24Intermediary (Mediator)

3Reliability

If estradiol dosage is increased to improve clinical response, then treatment efficacy improves, but safety concerns increase

Engineering Contradiction:
Core Design Contradiction:
ReliabilityVSObject-affected harmful factors

Solution Approach 1:

The patent implements dynamics by creating a controlled-release formulation where the estradiol release rate can be adjusted based on patient response. The solubilized formulation in oil-based carriers provides sustained release over extended periods, allowing for lower total dosages compared to conventional forms. This dynamic release profile maintains therapeutic efficacy while reducing peak concentrations that would cause safety concerns.

Inventive Principle:
Principle #15Dynamics

Solution Approach 2:

The patent changes the pharmacokinetic parameters of estradiol delivery through solubilization in specific carriers and adjustment of formulation composition. By optimizing the carrier type, concentration, and release characteristics, the formulation achieves improved clinical response at lower dosages. The parameter optimization balances efficacy and safety by controlling the rate and extent of estradiol absorption.

Inventive Principle:
Principle #35Parameter changes

Applied Scientific Principles

This section explains which scientific principles are used to turn an abstract innovation direction into a practical engineering solution.

Function Achieved in This Case

The soft gel vaginal composition provides effective treatment for VVA and FSD by improving patient compliance, reducing vaginal discharge, and enhancing clinical parameters like vaginal pH, superficial cell percentage, and dyspareunia severity, with adjustable dosages for personalized treatment.

Implementation Method 1

a dosage form comprising the estradiol is manually or digitally inserted

Methodology Applied
Scientific EffectManual or digital insertion:

Implementation Method 2

The soft gel vaginal pharmaceutical composition eases vaginal administration, provides improved safety of insertion, minimizes vaginal discharge following administration, and provides a more effective dosage form having improved efficacy

Methodology Applied
Scientific EffectAbsorption: Absorption (physical)

Data Source

PatentUS20250387339A1Vaginal inserted estradiol pharmaceutical compositions and methods
Publication Date: 2025.12.25
  • US20250387339A1 patent drawing
  • US20250387339A1 patent drawing
  • US20250387339A1 patent drawing

AI summary

Disclosed herein is, among other things, a soft gel vaginal pharmaceutical composition and dosage form containing solubilized estradiol for the treatment of vulvovaginal atrophy (VVA) and female sexual dysfunction (FSD).